Table 3.
Neutrophil and platelet engraftment in patients <60 and ≥60 years of age.
| 3101 Study (NHL) | 3102 Study (MM) | |||||||
|---|---|---|---|---|---|---|---|---|
| <60 years | ≥60 years | <60 years | ≥60 years | |||||
| Plerixafor + G-CSF (n = 85) |
Placebo + G-CSF (n = 47) |
Plerixafor + G-CSF (n = 50) |
Placebo + G-CSF (n = 35) |
Plerixafor + G-CSF (n = 74) |
Placebo + G-CSF (n = 69) |
Plerixafor + G-CSF (n = 68) |
Placebo + G-CSF (n = 67) |
|
| Median infused CD34+ cell dose/kg (range) |
5.9 (2.1-17.6) |
3.6 (2.0-8.7) |
5.1 (2.0-13.5) |
4.3 (2.2-8.3) |
5.3 (2.0-16.7) |
4.0 (1.8-16.9) |
5.6 (1.2-16.1) |
3.9 (1.8-15.4) |
| Median time to neutrophil engraftment (range), days |
10 (8-14) |
11 (8-13) |
10 (8-30) |
10 (9-13) |
11 (2-17) |
11 (9-21) |
11 (9-29) |
11 (9-21) |
| Median time to platelet engraftment (range), days |
20 (9-104) |
20 (15-97) |
20 (9-69) |
21 (13-98) |
19 (1-57) |
19 (1-95) |
18 (1-92) |
18 (1-45) |
Note: Every patient on 3103 achieved successful neutrophil engraftment. Only one patient on 3102 did not achieve neutrophil engraftment, whereas four patients on 3103 and two patients on 3102 did not achieve successful platelet engraftment.